Practical Considerations for Zenocutuzumab in NRG1 Fusion–Positive Malignancies

AI may open pathways to locate pancreatic cancer earlier and in higher-risk patient subgroups, according to Debiao Li, PhD, and Stephen Pandol, MD.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

The rare nature of pancreatic cancer makes identifying it difficult, but progress towards earlier identification is being made, according to Brian M. Wolpin, MD, MPH.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Tumor treating fields with chemotherapy improved overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma.

Shubham Pant, MD, MBBS, highlights how pan-RAS inhibitors, RAS-directed vaccines, and biomarker testing can improve outcomes in pancreatic cancer.